ST. LOUIS, Dec. 27, 2010 /PRNewswire-FirstCall/ — K-V
Pharmaceutical Company (NYSE: KVa/KVb) today announced the filing
of its Form 10-K for its fiscal year ended March 31, 2010 with the
Securities and Exchange Commission. As a result, the Company
has met the deadline for filing its delayed fiscal 2010 Form 10-K
to enable its securities to continue trading on the New York Stock
Exchange.
The Company is currently working on preparing and filing its
quarterly reports on Form 10-Q for the quarters ended June 30, 2010
and September 30, 2010 and will file these reports as soon as they
are completed. The Company’s Form 10-Q for the quarter ending
December 31, 2010 will be due on February 9, 2011. The
Company currently expects that it will be unable to timely file
this report.
Greg Divis, KV’s Chief Executive Officer stated, “We are pleased
to have filed our Form 10-K for fiscal 2010 and continue to work
diligently and as quickly as possible to file the remaining
outstanding quarterly reports to enable us to return to a current
and timely filer with the Securities and Exchange Commission.
The Company continues to move forward as we focus on
returning additional products to the market prior to our 2011
fiscal year-end and to the approval and launch of
Gestiva™.”
About K-V Pharmaceutical Company
K-V Pharmaceutical Company is a fully-integrated specialty
pharmaceutical company that develops, manufactures, markets, and
acquires technology-distinguished branded prescription
pharmaceutical products. The company markets its
technology-distinguished products through Ther-Rx Corporation, its
branded drug subsidiary. For further information about K-V
Pharmaceutical Company, please visit the company’s corporate Web
site at www.kvpharmaceutical.com.
Cautionary Note Regarding Forward-looking Statements
This press releases contains various
‘/>”/>
